Tyverb / Tykerb (lapatinib) 250 mg, 30 tablets, India, generic Tykerb (lapatinib) is used for certain HER2-positive breast cancers. International medicine delivery. Order at +380996042415 via Viber or WhatsApp.
- Delivery of non-temperature-controlled medicines to Chisinau - $25.
Delivery of temperature-controlled medicines to Chisinau - $50.
Up to 5 packages can be sent per shipment. The price applies to one shipment. - Pickup from Odesafree
- Shipping within Ukraine by Nova Poshta at the carrier's rates.
Payment in UAH upon receipt of the order.
Delivery time
- Originator medicines: 5-7 days
- Generic medicines: 3-4 days
- Bank transfer to the settlement account after receiving the order
- Payment upon pickup in Odesa
Tykerb / Tyverb / lapatinib
indications
Treatment of adult patients with breast cancer with overexpression of HER2 (ErbB2):
as part of combination therapy with capecitabine for patients with advanced or metastatic cancer that has progressed on previous therapy with trastuzumab in combination with anthracyclines and taxanes due to metastatic disease;
as part of combination therapy with trastuzumab in patients with metastatic, hormone-negative cancer, progressing after trastuzumab-containing chemotherapy;
as part of combination therapy with an aromatase inhibitor for postmenopausal women with metastatic, hormone-positive cancer who are not prescribed chemotherapy. Patients in the registration study were not pretreated with trastuzumab or aromatase inhibitors. There is no data on the effectiveness of this combination compared to trastuzumab in combination with an aromatase inhibitor in this group of patients.
Dosage and administration
The course of treatment is prescribed only by a doctor with experience in the use of anticancer drugs.
Before starting treatment, it is necessary to determine the level of left ventricular ejection fraction in order to ensure that its initial level is within the established norms (see Section "Features" application"). Monitoring of the level of left ventricular ejection fraction should continue during treatment with Tyverb to ensure that its decrease does not reach below acceptable standards (see “Discontinuation or dose reduction”, “Cardiovascular system”).
Tayverb should be taken 1:00 before or 1:00 after meals (see Section “Pharmacokinetics”). The recommended daily dose of Tyverb should not be divided. To reduce patient-to-patient variability, Tyverb use should be standardized relative to meal intake, for example, the drug should always be taken one hour before meals.
Missed doses of the drug should not be taken additionally; the next dose of the drug should be continued according to the schedule of use (see Section “Overdose”).
When used together with other drugs, you must read the instructions for use of these drugs.
Tyverb in combination with capecitabine.
The recommended dose of Tyverb is 1250 mg (5 tablets) 1 time per day daily.
The recommended dose of capecitabine is 2000 mg/m2/day in 2 divided doses (every 12:00) every day from the 1st to the 14th day of the 21-day treatment cycle. It is recommended to take capecitabine with food or within 30 minutes after a meal.
Tyverb in combination with trastuzumab
The recommended dose of Tyverb is 1000 mg (4 tablets) 1 time per day daily.
The recommended dose of trastuzumab is - 4 mg/kg body weight as a loading dose, then 2 mg/kg body weight once a week.
Tayverb in combination with an aromatase inhibitor.
The recommended dose of Tyverb is 1500 mg (6 tablets) once daily.
The recommended dose of the aromatase inhibitor letrozole is 2.5 mg once a day. When using Tyverb with an alternative aromatase inhibitor, you should read the instructions for use of this drug.
